+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Orexo AB - logo

Orexo AB is a specialty pharmaceutical company in the United States. Its launched products include Zubsolv sublingual tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, an active substance zolpidem that is used for the treatment of short-term insomnia. It has collaboration agreement with Mundipharma for the development and commercialization of Zubsolv and with AstraZeneca with regards to the OX-Cysteinyl Leukotriene Inhibitor project. Founded in 1995, the company is headquartered in Uppsala, Sweden.

From
Opioid Drugs: Global Markets to 2023 - Product Thumbnail Image

Opioid Drugs: Global Markets to 2023

  • Report
  • November 2018
  • 147 Pages
From
Opioid Related Disorder - Pipeline Insight, 2021 - Product Thumbnail Image

Opioid Related Disorder - Pipeline Insight, 2021

  • Clinical Trials
  • September 2021
  • 80 Pages
From
From
From
Opium (Opioid) Addiction - Pipeline Review, H2 2020 - Product Thumbnail Image

Opium (Opioid) Addiction - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 193 Pages
From
From
Opium (Opioid) Addiction Global Clinical Trials Review, H1, 2020 - Product Thumbnail Image

Opium (Opioid) Addiction Global Clinical Trials Review, H1, 2020

  • Clinical Trials
  • February 2020
  • 437 Pages
From
From
From
From
Loading Indicator